1 ry distress syndrome caused by coronavirus 2019 (COVID-
19),
mortality remains high despite optimal medical management.
2 fewer were ideal for guideline-based therapy, and
absolute mortality remains high, suggesting the need for treatment str
3 In
Africa,
mortality remains high because there is limited access to tre
4 sive therapies, the burden of recurrent ischemic events
and mortality remains high, and future research is ongoing to pre
5 for acute respiratory distress syndrome (ARDS) exists,
and mortality remains high.
6 fungal infections are common in critically-ill patients
and mortality remains high despite antimicrobial therapy.
7 st two decades, yet gaps in the quality of care persist
and mortality remains high.
8 y to improve, but the prognosis for the disease is poor
and mortality remains high.
9 ensive clinical research to improve the management of
ARDS,
mortality remains high, and few strategies have shown a morta
10 arrest resuscitation and postarrest resuscitation care,
but mortality remains high.
11 ients with heart failure and reduced ejection fraction,
but mortality remains high.
12 acute respiratory distress syndrome (ARDS) management,
but mortality remains high.
13 Childhood mortality remains high in low-resource settings, where enviro
14 In rural India, as in many developing countries,
childhood mortality remains high and the quality of health care availab
15 Despite reductions over the past 2 decades,
childhood mortality remains high in low- and middle-income countries in
16 In the US,
CKM mortality remains high and disproportionately occurs in more
17 However, 30-
day mortality remains high in these patients.
18 Hepatocellular carcinoma (
HCC)
mortality remains high primarily due to late diagnosis as a c
19 Despite in-
hospital mortality remains high, venoarterial extracorporeal membrane
20 complication rates are generally low, although in-
hospital mortality remains high.
21 However,
mortality remains high for many cancers, especially in the me
22 However,
mortality remains high in patients with distant recurrence of
23 However,
mortality remains high, at 8% in children and 15% in adults i
24 ve steadily improved in the past decade in Malawi;
however,
mortality remains high in specific subgroups.
25 fesaving intervention for critically ill patients;
however,
mortality remains high.
26 ommon and lethal syndrome: although outcomes have
improved,
mortality remains high.
27 Despite some
improvements,
mortality remains high at 30-40% in most studies.
28 in clinical outcomes following acute myocardial
infarction,
mortality remains high, especially in patients with severely
29 f patients with ST-segment elevation myocardial
infarction,
mortality remains high.
30 ith PML who were treated with immune checkpoint
inhibitors,
mortality remains high.
31 isk patients are selected for nonurgent transplant
listing,
mortality remains high, even among those who survive the init
32 ritically ill patients, and despite advances in
management,
mortality remains high.
33 ing malignant pleural mesothelioma with various
modalities,
mortality remains high, with median survival between 12 and 1
34 Moreover,
mortality remains high (~50%) in low-resource settings.
35 the number of facility-based births, maternal and
neonatal mortality remains high.
36 Overall mortality remains high and mainly related with host factors.
37 logical treatment for patients with heart failure,
residual mortality remains high.
38 Short-
term mortality remains high for elderly patients with acute myocar
39 Despite significant advances in care, however,
the mortality remains high (30-100%).
40 s a desirable new direction for pancreatic cancer where
the mortality remains high despite the current care and intense r
41 Despite progress with the approval of novel
therapies,
mortality remains high; approximately half of the people diag
42 spite significant improvements in prevention and
treatment,
mortality remains high for many cancer types.
43 Despite improved pharmaceutical
treatments,
mortality remains high.
44 mpirical inotropic therapy (with or without a
vasodilator),
mortality remains high.
45 After salvage TIPS, 6-
week mortality remains high and can be predicted by MELD score and